Efficacy Study of IL-21 to Treat Metastatic Melanoma
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At
least 14 to a maximum of 40 patients, who have not previously received treatment for their
stage IV disease, will be treated for 6 weeks. IL-21 will be administered intravenously.